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Abstract
Background: Women ages 16–29 utilizing family planning clinics for medical services experience higher rates of
intimate partner violence (IPV) and reproductive coercion (RC) than their same-age peers, increasing risk for
unintended pregnancy and related poor reproductive health outcomes. Brief interventions integrated into routine
family planning care have shown promise in reducing risk for RC, but longer-term intervention effects on partner
violence victimization, RC, and unintended pregnancy have not been examined.
Methods/Design: The ‘Addressing Reproductive Coercion in Health Settings (ARCHES)’ Intervention Study is a cluster
randomized controlled trial evaluating the effectiveness of a brief, clinician-delivered universal education and
counseling intervention to reduce IPV, RC and unintended pregnancy compared to standard-of-care in family planning
clinic settings. The ARCHES intervention was refined based on formative research. Twenty five family planning clinics
were randomized (in 17 clusters) to either a three hour training for all family planning clinic staff on how to deliver the
ARCHES intervention or to a standard-of-care control condition. All women ages 16–29 seeking care in these family
planning clinics were eligible to participate. Consenting clients use laptop computers to answer survey questions
immediately prior to their clinic visit, a brief exit survey immediately after the clinic visit, a first follow up survey 12–20
weeks after the baseline visit (T2), and a final survey 12 months after the baseline (T3). Medical record chart review
provides additional data about IPV and RC assessment and disclosure, sexual and reproductive health diagnoses, and
health care utilization. Of 4009 women approached and determined to be eligible based on age (16–29 years old),
3687 (92 % participation) completed the baseline survey and were included in the sample.
Discussion: The ARCHES Intervention Study is a community-partnered study designed to provide arigorous
assessment of the short (3-4 months) and long-term (12 months) effects of a brief, clinician-delivered universal
education and counseling intervention to reduce IPC, RC and unintended pregnancy in family planning clinic settings.
The trial features a cluster randomized controlled trial design, a comprehensive data collection schedule and a large
sample size with excellent retention.
Trial Registration: ClinicialTrials.gov NCT01459458. Registered 10 October 2011.
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Background
Women ages 16–29 years seeking care in family planning
(FP) clinics report higher rates of intimate partner vio-
lence (IPV) compared to their same-age peers; [1–7] these
negative experiences are, in turn, associated with unin-
tended pregnancy and related poor sexual and reproduct-
ive health outcomes [8–19]. A growing body of literature
on male partner influences on contraception and preg-
nancy decision-making has identified a range of male part-
ner pregnancy-controlling behaviors that contribute to
poor reproductive and sexual health outcomes for women
[7, 20–23]. Reproductive coercion (RC) is defined as male
partners’ attempts to promote pregnancy in their female
partners through verbal pressure and threats (pregnancy
pressure), direct interference with contraception (birth-
control sabotage), or threats and violence related to preg-
nancy continuation or termination (control of pregnancy
outcomes) [1, 7, 24, 25]. In our pilot intervention study,
53 % of young women using FP clinics reported ever
experiencing IPV, and 25 % reported reproductive coer-
cion, the combination of which was strongly associated
with increased prevalence of unintended pregnancy [26].
In light of increased sexual and reproductive health
concerns and care utilization among IPV victims, as well
as the success of clinic-based interventions regarding
other behaviorally-based health issues, [27–32] multiple
calls for clinic-based interventions for IPV have emerged
[33–38]. Unfortunately, screening and disclosure rates
remain low; existing studies on disclosure indicate that
only 5 % to 15 % of women have disclosed abuse to their
providers [39–41]. Survivors’ preferences not to be pres-
sured to disclose [42–44] and health provider discomfort
with discussing IPV [45–47] compound the difficulties
in identifying and supporting survivors [34, 44, 48–55].
IPV screening alone, in the absence of counseling inter-
ventions, has not been found to be effective in reducing
IPV or other related health outcomes for women [56, 57].
Thus, interventions that provide information and support
for all women seeking clinical care and facilitate routine
discussion of IPV within the clinical context are indicated
[58, 59]. Evidence that abused women also face reproduct-
ive coercion (RC) suggests the promise of integrating dis-
cussion of RC within IPV assessment to facilitate women’s
recognition of these interrelated issues. To our knowledge,
the ARCHES intervention is the first to include formal as-
sessment of RC for women seeking reproductive health
services and to facilitate patient and provider discussion of
RC and related abusive experiences.
The ARCHES (Addressing Reproductive Coercion in
Health Settings) intervention was developed collabora-
tively by researchers, advocates and community-based
practitioners, with significant input from FP clients [26].
Providers are trained to conduct the three components of
the ARCHES intervention: 1) universal client education
and assessment regarding IPV and RC; 2) discussion of
harm reduction behaviors to reduce risk for unintended
pregnancy, IPV victimization, and RC; 3) supported refer-
rals to IPV victim services (including provision of IPV
related resources to all clients regardless of disclosure).
ARCHES is designed to be implemented within routine FP
care, maximizing its feasibility, sustainability and scalability.
In the initial pilot randomized intervention trial, among
women who at baseline reported experiencing IPV in the
past 3-months, the original version of ARCHES reduced
the odds of recent pregnancy coercion (a component of
RC) at follow-up assessment (3 to 6 months post-baseline)
by 71 % compared to the control, highlighting the potential
impact of this intervention [26]. Based on this pilot, we
designed a large-scale cluster randomized controlled clin-
ical trial (RCT) (i.e., sufficiently powered and of adequate
duration) to assess the short (3–4 month) and long-term
(12 month) effects of this innovative program on IPV and
RC (primary outcomes) as well as unintended pregnancy
(secondary outcome) – major and prevalent health threats
among medically underserved women.
ARCHES is being evaluated in 25 FP clinics in Western
Pennsylvania randomized to either intervention or control
(i.e., standard-of-care) conditions. Participating female FP
clients ages 16–29 (N = 3687) complete assessments at
baseline (T1), 12–20 weeks (T2), and 12 months (T3) to
assess intervention effects on knowledge and behaviors
related to IPV, RC and related harm reduction, as well as
unintended pregnancy. Survey data at each time point are
collected via audio computer assisted self-interview in
English or Spanish. Chart data abstracted from client
medical records allow tracking of clinic utilization, preg-
nancy testing, and diagnosed pregnancies one year prior
to baseline through 18 months post-baseline. Intervention
effects on patient-level outcomes at follow-up will be
assessed using multilevel regression analyses that account
for clustering of individual participants within clinics, the
units of randomization. All project partners, including cli-
ent and clinician advisors, participate in interpretation of
results and dissemination of findings.
Methods/Design
Overview of RCT design
The ARCHES Intervention Study was designed as a strati-
fied, parallel-group cluster randomized controlled trial
comparing the ARCHES intervention to standard-of-care
for family planning clients (Fig. 1 and Table 1). Because
ARCHES is designed to facilitate changes in clinical cul-
ture related to how abuse is handled, a cluster randomized
design was required to avoid contamination that could
arise from within-cluster randomization of patients or
providers. Family planning clinics were classified as rural
or urban location based on U.S. Census and Federal Regis-
ter data from the Bureau of Commerce [60], grouped into
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Fig. 1 Study design, including timing of assessments and targeted enrollment. Patients in this cluster randomized trial are scheduled for
assessments at three timepoints. The targeted enrollment was based on power calculations with cautious assumptions regarding patient
retention at follow-up timepoints
Table 1 Outcome measures and data collection points
Outcomes Participant survey measurement points Chart Abstraction Data Measures
T1 T2 T3
Prior to
clinical visit
Immediately
after clinic visit
12–20
weeks
1 year 12 months pre-baseline
to 18 months
post-baseline
Primary Outcomes
Recent reproductive coercion X X X 10 items, investigator-developed
(summary score)
Recent physical and sexual
partner violence victimization
X X X Conflict Tactics Scale-2 (CTS2;
1 item on physical violence) [91]
Sexual Experiences Survey
(2 items on sexual violence)
[86] (summary score)
Secondary Outcomes
Unintended pregnancya X X X Self-report 7 items from
National Survey of Family
Growth (summary score);
electronic medical record data1
Recognition of sexual
and reproductive coercion
X X X 9 items, investigator-developed
(mean score)
Self-efficacy to implement
harm reduction strategies
X X 4 items, investigator-developed
(mean score)
Knowledge of IPV-related
resources and services
X X 5 item checklist of national and
local resources (summary score)
Use of harm reduction strategies X X 6 items, investigator-developed
(summary score)
Additional Secondary Outcomes (restricted to those reporting physical or sexual partner violence or RC at baseline)
Use of IPV-related
resources and services
X X 5 item checklist
of national and local
resources (summary score)
Disclosure to health
care provider Reproductive coercion
X Two items on telling HCP
about IPV or RC experiences
Intervention Implementation (to assess intensity of intervention received for as-treated analyses)
Conversation with HCP about
healthy and unhealthy relationships
X 1 item, self-report
Receipt of safety card X 1 item, self-report
aInformation is assessed both via self-report and medical record data, such that the greater value of the two data sources is used for analyses
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clusters based on shared providers, stratified by cluster
size and then randomly assigned either to receive provider
training on the ARCHES intervention and implement this
with all clinic visits or to continue their usual assessment
and care for domestic violence. Randomization provided
each clinic an equal probability of being in either arm. To
ensure balance, randomizations resulting in a between-
arm imbalance in the number of rural clinics of 5 or
greater were not allowed.
Patients in both arms complete surveys at baseline prior
to their clinical visit, immediately following their clinical
visit, 12–20 week follow-up, and 1 year follow-up (Fig. 1).
Surveys are completed using laptops with audio computer-
assisted self-interview (ACASI) at baseline; follow-up
surveys are also completed via ACASI (for clients able to
come to clinic) or via an online survey sent via email (for
18 years of age or older) or by telephone for women
unable to return to the clinic. Following completion of
survey data collection, electronic medical record (EMR)
data are abstracted for defined intervals within the time
period one year prior to baseline and up to 18 months
post baseline (Fig. 2).
Description of intervention
Relevant rationale, history and format of the ARCHES
intervention
This study evaluates a family planning clinic-based IPV
and reproductive coercion (RC) intervention developed
by a team of researchers, victim service advocates, and
reproductive health practitioners [61]. Figure 3 describes
the conceptual model of the ARCHES Intervention and
Hypothesized Outcomes. One innovation of the ARCHES
intervention is the focus on training not only clinicians, but
also para-medical providers (i.e., medical assistants, health
educators, and family planning counselors working in these
settings) to discuss IPV and RC when counseling around
contraception, pregnancy or STI testing. Additionally, the
emphasis on universal provision of IPV/RC information
recognizes that women often do not recognize IPV or RC
and may not define sexual coercion as abuse, [62, 63]
particularly when the perpetrator is known to them [63].
The lack of recognition of abusive behaviors in relation-
ships [42, 43] has been associated with decreased IPV help-
seeking, [63–65] highlighting need for universal IPV/RC
education and enhanced assessment.
ARCHES provides universal IPV/RC education and en-
hanced assessment through FP provider discussion of
IPV/RC with their patients in a way that highlights the
prevalence of such abuse among women seen at the clinic
and educates patients about the reproductive health im-
pact of such abuse. The enhanced assessment for IPV/RC
integrates into the reproductive health visit, for example,
by asking a woman seeking pregnancy testing whether her
partner might be pressuring her to get pregnant. This edu-
cation and assessment is facilitated by the use of a palm-
sized brochure which describes healthy and unhealthy re-
lationships, offers information about harm reduction, and
provides IPV related resources. Evidence that clinic-based
IPV assessment can be the first step in recognizing abuse,
particularly when done in a context that normalizes such
abuse experiences, [42, 66] strengthens the rationale for
locating IPV and RC assessment within the context of
supportive education for all women seeking FP services.
ARCHES also counsels women on harm reduction strat-
egies. Harm reduction, originally used within substance
abuse treatment, has been effective in managing a range of
health risk behaviors [67] by ‘meeting clients where they
are’ and assisting them with identifying strategies to
decrease harm, including harms related to sexual health
[68–71]. IPV interventions appear to increase safety
Fig. 2 Definition of intervals for use in electronic medical record abstraction. To match the reporting periods spanned by the T1, T2 and T3
surveys, events identified in electronic medical record (EMR) data are assigned to patient-specific intervals using the displayed definitions
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planning and harm reduction behaviors among victimized
women, e.g., increase ability to refuse sex, [72] reduce sub-
stance use in dating contexts, [73] and advance preparation
for safe escape should violence escalate [74]. Harm reduc-
tion behaviors have also been shown to protect against
violence victimization among high-risk groups (i.e., women
in prostitution), [75] and to reduce revictimization among
college women [73]. Thus, ARCHES is designed to reduce
women’s risk for violence victimization and unintended
pregnancy via education regarding non-partner dependent
contraceptives (longer acting reversible contraceptives such
as the intrauterine device), access to emergency contracep-
tion, and provision of harm reduction strategies.
Finally, supported “warm” referrals (i.e., provider facilita-
tion of referral to a victim service advocate via phone or in
person) can assist clients in overcoming common barriers
to accessing services, including self-blame, [43, 76] lack of
recognition of abuse, [63, 64] lack of knowledge of services,
[43, 76, 77] and perception that services are limited in
scope (e.g., solely crisis oriented) [76]. Articulating the
scope of services available to all women (regardless of
disclosure of IPV or RC experiences), and normalizing
use of these services may facilitate awareness and use
of IPV services, improve mental health symptoms,
[78–81] and reduce revictimization [82–84].
Training of intervention sites
Nine clusters (11 clinics) were randomized to the inter-
vention. In these clinics, family planning clinic staff (family
planning counselors, medical assistants, and clinicians)
were trained to educate clients about the links between re-
productive health concerns and intimate partner violence/
sexual assault (“enhanced screening”); counsel clients on
harm reduction behaviors to reduce risk for IPV/RC
(“harm reduction”); and provide clients with information
on violence victimization support services (“supported
‘warm’ referrals”) with the goal of reducing IPV/RC and
unintended pregnancy. The training, led by one of the PIs
and the lead trainer from Futures without Violence (the
non-profit violence prevention organization collaborating
on this study), involved a half-day (approximately 3 h)
introduction on the prevalence of IPV/RC, instruction on
how to conduct universal IPV/RC client education with
the aid of the palm-sized brochure, and role playing to
practice IPV/RC assessment and provide harm reduction
counseling for specific clinical scenarios (such as preg-
nancy testing). Training materials included copies of the
reproductive health palm-sized brochure, reproductive
health care setting medical guidelines, slides describing
the prevalence of IPV and RC and relevance for family
planning services, and video vignettes illustrating common
reproductive health visits demonstrating with actors how
to implement this universal education and brief counsel-
ing intervention.
Approximately 1–3 months after the initial training, in
conjunction with starting data collection, a 30-minute re-
fresher training was conducted by the study coordinator,
to review key points of the training and provide opportun-
ity for providers to ask clarifying questions about the
intervention to increase fidelity.
Assessing fidelity to intervention
To maintain quality of intervention delivery and track fi-
delity to the intervention, data collected from client exit
surveys (brief surveys completed by clients as soon as
their clinic visit was over) were summarized on a weekly
basis, and sent via email to the office manager of each
intervention site. The data highlighted client responses to
two questions: “Today, did your health care provider talk
with you about healthy and unhealthy relationships?” and
“Today, did your health care provider give you a card
called” Do You Know Your Relationship Affects Your
Health?“talking about partner’s control of pregnancy and
your reproductive health?” The proportion of clients
Fig. 3 Conceptual model for ARCHES
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reporting they had had this discussion and had received
the palm-sized brochure was reported weekly to each of-
fice manager, with the study coordinator offering sugges-
tions on strategies to increase provider discussions and
card delivery.
Control condition
Eight clusters (14 clinics) were randomized to the standard-
of-care (‘control’) condition, meaning they continued diag-
nostic and treatment procedures as clinic staff typically
would for their patients with no additional training. In
discussions of sexual health or pregnancy risk, IPV may be
discussed, but no training on or provision of protocols
related to IPV education or referral were included as
standard-of-care. Apart from such standard care, at the con-
clusion of the exit survey at the baseline clinic visit, control
group participants received written materials regarding
community resources which included IPV resources mixed
in with other information around housing, food, and social
services. Assigned to a wait-list condition, a control site
could opt to receive the ARCHES intervention training fol-
lowing the completion of follow-up data collection.
Outcome measures
Primary outcomes
Reproductive coercion Recent (past 3 months) repro-
ductive coercion, specifically, pregnancy pressure and
birth control sabotage, is assessed using a scale of 10
items (e.g., Has someone you were dating or going out
with: “said he would leave you if you didn’t get pregnant”
and “made you have sex without a condom so you would
get pregnant” (Cronbach alpha = 0.74)) [1, 7]. A sum-
mary score tallies the number of behavior items experi-
enced, for a maximum score of 10.
Recent physical and sexual partner violence victimization
Past three month physical and sexual partner violence are
measured using one item modified from the Conflict Tac-
tics Scales-2 [85] for physical violence (i.e., hit, pushed,
slapped, choked or otherwise physically hurt by some-
one they were dating or going out with) and two items
from the Sexual Experiences Survey [86] for sexual
violence (being made to do something sexual with and
without the use of force or threats) (Cronbach alpha = 0.46).
The outcome is modeled as a summary score (maximum
value of 3 if a participant experienced all 3 actions).
Secondary outcomes
Incident and unintended pregnancy Incident pregnan-
cies are measured using two methods: a single survey
item asking how many times the client had been preg-
nant in the past 12 months, including miscarriages and
abortions, and chart abstraction data indicating a
positive pregnancy test, not receiving a pregnancy test
because patient is currently pregnant, or receiving pre-
natal care. The greater of self-reported pregnancies or
chart abstraction data on pregnancy diagnoses is counted
as the total number of incident pregnancies for that client
in each time interval (12 months prior to baseline and
18 months after baseline).
Self-reported unintended pregnancy is measured via 7
items from the National Survey for Family Growth, as rec-
ommended by Santelli and colleagues to assess pregnancy
intention (i.e., desire and timing) [87]. Women who reported
any pregnancy in the past 12 months are asked, for their
most recent pregnancy, three dichotomous items about the
timing (mistimed), planning (unplanned), and desire to have
a baby with their current partner (not desired). Four scaled
items ask about how much they wanted to be pregnant
(“wanted to avoid” to “wanted to get pregnant”), how much
they were trying to get pregnant (“not trying” to “really trying
hard”), trying to avoid getting pregnant (“trying to avoid” to
“not trying to avoid”), and how happy they were when they
found out they were pregnant (“very unhappy” to “very
happy”). For each of these four items, the scale is from zero
to 4, with responses of zero and 1 coded as unintended. In
multivariate analyses, these 7 items were unidimensional
[88]. Thus, a summary score from responses to all 7 items
is created to measure the degree of unintendedness of the
pregnancy, ranging from 1 to 7 (Cronbach alpha = 0.94).
Women with no pregnancy in the past year and women
who had been pregnant but have no ‘unintended’ re-
sponses to the above 7 items are coded as zero (i.e., no
unintended pregnancy).
Recognition of sexual and reproductive coercion
A scale of 9 items was developed by the investigators to
assess participants’ perceptions of how abusive behaviors
specific to sexual and reproductive coercion are (e.g.,
“trying to make someone have an abortion when they
don’t want one” and “pressuring someone to have sex
when they’ve said no”). Participants are asked to rate the
behaviors on a 4-point Likert scale from “not abusive” to
“extremely abusive” (Cronbach alpha = 0.86). The out-
come is measured as a mean score of the 9 responses
with a higher score indicating greater perception of
abusiveness.
Self-efficacy to implement harm reduction strategies
Participants are presented with four statements that are de-
signed to assess level of confidence in implementing
behaviors to reduce the impact of reproductive and sexual
coercion (e.g., “If my sexual partner is keeping me from
using birth control, I am confident I could ask a healthcare
provider about other kinds of birth control that my partner
can’t mess with.”). Responses are rated on a 5-point Likert
scale from “strongly agree” to “strongly disagree” with the
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outcome modeled as a mean response to the 4 items
(Cronbach alpha = 0.72). To reduce measurement effect
(i.e., the survey items themselves increasing women’s know-
ledge of harm reduction strategies), this construct is
assessed at follow-up visits only (T2 and T3).
We also collected a general self-efficacy measurement at
baseline, using The New General Self-Efficacy scale (NGES)
developed by Chen, Gully, and Eden [89] to acquire the stat-
istical power-enhancing advantages of a baseline covariate
that is correlated with the above self-efficacy outcome, but
whose assessment would not lead to a “measurement effect.”
The NGES consists of 8 items (e.g., “Even when things are
tough, I can perform quite well.”) with response options on
a 5 point Likert scale (“strongly agree” to “strongly disagree”)
(Cronbach alpha = 0.89). General self-efficacy is modeled as
the mean response to these items and the baseline value is
included as a covariate in the models assessing self-efficacy
to implement harm reduction strategies.
Use of harm reduction strategies
Use of 6 harm reduction strategies to decrease the oc-
currence and impact of reproductive and sexual coercion
and unsafe relationships was assessed at both follow-up
visits. Participants are asked to endorse whether they
had used these strategies (e.g., “have you hidden your
birth control from your partner because you were afraid
he would get upset with you for using it” and “have you
tried to protect yourself from your partner by asking fam-
ily or friends to call or text you when you were with that
partner”) in the past 3 months (Cronbach alpha = 0.39).
The outcome is modeled as a summary score with a max-
imum value of 6 (one point per each strategy endorsed).
To prevent measurement bias, this construct is assessed
at follow-up visits only (T2 and T3).
Knowledge of IPV-related resources and services
To assess knowledge of IPV-related resources and services,
participants are presented a list of resources and asked to
endorse each one for which they “had received information
on in the past 3 months” (Cronbach alpha = 0.80). Listed
resources included Domestic Violence Advocacy Services,
Rape Crisis Center, National Domestic Violence Hotline,
Teen Dating Abuse Helpline, and Loveisrespect.org. A
summary score is calculated with one point per resource
selected for a maximum score of 5. To reduce the possibil-
ity of participants endorsing items because they had seen
the resources identified in earlier surveys, this measure was
not included in the baseline survey.
Additional secondary outcomes for women with recent
history of IPV or RC
In addition to the above outcomes, two additional out-
comes are included for analyses restricted to women
who endorsed any physical or sexual violence or RC at
baseline, as this group was hypothesized to receive the
greatest benefit from the intervention. For convenience,
we refer to this analysis subset as the “Aim 2” analysis,
with the full population analyses described as “Aim 1”
analyses.
Use of IPV-related resources and services
Participants are asked to endorse all IPV-related resources
that they used in the past 3 months from the same list
presented in the measure of knowledge of IPV-related re-
sources and services (above) (Cronbach alpha = 0.55). As
with the knowledge measure, this question is presented at
follow-up visits only (T2 and T3). The outcome is mod-
eled as a summary score, tallying number of endorsed
items.
Disclosure to a health care provider was assessed at T3
only with two questions: whether in the past 12 months
the client told a health care provider about ever being in
an unhealthy or unsafe relationship or about a partner
trying to get her pregnant when she didn’t want to be,
messing with birth control, or controlling a pregnancy.
Setting
Patients were recruited from 25 family planning clinics affil-
iated with Planned Parenthood of Western Pennsylvania
and Adagio Health from both urban and rural areas within
a 150 mile (3 h) radius of Pittsburgh, Pennsylvania. All were
free-standing family planning clinics; family planning ser-
vices embedded within community health centers were
excluded. Some clinics were combined into clusters (n = 17
clusters) to account for shared staff and providers that
could otherwise lead to contamination between the two
arms of the trial.
Randomization procedures, including choice of unit of
randomization
The unit of randomization was clinic clusters comprised of
one or a small number of clinics sharing a common set of
healthcare providers. We chose a clinic-level cluster-
randomized design to prevent contamination of the
control condition (standard of care). Given that a main
component of this intervention was training health
care providers how to facilitate conversations with
patients about threats to reproductive and sexual
health (such as RC and IPV), it would not be feasible
or appropriate to request a provider to initiate conver-
sations with only a subset of patients, which would be
the case if the study had used individual client-level
randomization. A second component of the interven-
tion was to connect clinics to domestic violence advo-
cates to facilitate referrals to community violence
resources; this clinic-level component precluded the
use of provider-level randomization. The study was also
intended to assess the effectiveness of this intervention in
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“real world” clinical settings, i.e., with expected variability
in staff and provider comfort in addressing IPV and RC
and implementation of the intervention.
To ensure balanced assignment by clinic setting, each
cluster was labeled as urban or rural based on Census and
Department of Commerce Federal Register data [60].
Clinics with common providers were clustered together.
Randomization was stratified by cluster size and was de-
signed to give each cluster an even probability of being
randomized to intervention or control condition. Nine of
the 10 single-clinic clusters were rural, with five random-
ized to treatment. Of the 6 two-clinic clusters, 2 were
rural, 1 was urban and 3 were mixed. The randomization
assigned the three mixed clinics to the control condition.
The single 3-clinic cluster was all rural. It was assigned to
the control condition, as well. Had the randomization
resulted in a between-arm imbalance of 5 or greater rural
clinics (a 16.25 % probability), it would have been discarded
and a new randomization performed. Randomization was
performed using SAS software by the study’s lead statisti-
cian (DJT).
Participants: eligibility, recruitment and institutional
review board requirements
Description of IRB approval
The study was approved by the University of Pittsburgh
Institutional Review Board (IRB) on June 21, 2011 by
expedited review (Protocol Number PRO11050458). The
University’s IRB approval included a waiver for the re-
quirement to obtain a written informed consent to partici-
pate in the research, in order to reduce the risk for breach
of confidentiality (considered the primary risk associated
with this study); women were offered a copy of an infor-
mation sheet that was reviewed verbally with all clients.
For minors ages 16 and 17, a waiver of parental informed
consent for research participation was also approved by
the IRB to protect youth seeking confidential services at
these clinics from breach of confidentiality. A federal Cer-
tificate of Confidentiality was also obtained for the study
to protect research records from subpoena.
Additional safety precautions were in place to reduce risk
of harm to women for participating in the study, consistent
with international recommendations and best practices on
violence-related research [90]. Women who were at the
clinic with a male partner were only approached about the
study when they were alone. All follow up contacts made
about the study referred to the study as the “Women’s
Health Study.” To mitigate risk for emotional distress po-
tentially associated with taking a survey about IPV, all
research assistants were trained to ask women about how
they were feeling after taking the survey, offer a list of com-
munity resources (with IPV and sexual assault information
embedded among other less sensitive information about
housing and food), and to suggest women speak with the
clinical staff on site if they wished to talk more about the
survey questions. Additionally, if any woman disclosed to a
research assistant during survey administration that she
was concerned about her safety, research assistants were
trained to connect women with clinical staff as well as the
local victim service advocacy organization. Finally, for fol-
low up surveys conducted via email, women were encour-
aged to find a computer in a private space to complete the
survey and to erase the history after survey completion. For
those completing a follow up survey by phone, the re-
search coordinator would suggest a special ‘code phrase’
the woman could use if she needed to hang up because
someone else could overhear the conversation.
Procedures on Day of clinic visit
Research assistants (RAs) approached women in the
waiting room of FP clinics after they checked in for
their clinic visit if they were not in the presence of a
male partner and asked if they were here for a clinic
visit today, and whether they would like to hear about a
women’s health research study. If they were interested,
the RA assessed for eligibility. If eligible, potential par-
ticipants were brought to a private space in the clinic
to complete the consent process and survey administra-
tion. RAs let clinic staff know that the patient may be
interested in being in the study and would be taking
the survey before her appointment if she consented.
RAs explained to potential participants that they would
complete two surveys (one before and one immediately
after their clinic visit today) and receive a $15 gift card,
one survey in approximately 3 months for $25, and one
survey in 12 months for $40 to thank them for their time
and effort.
Prior to clinical encounter
Before participants’ appointments, they provided their con-
tact information (phone number and email address) and
two alternate contacts to the RA. RAs also went over the
verbal consent sheet, which provided details on why the
study was being conducted, the data collection process at
each of the three time points, the implications of the Cer-
tificate of Confidentiality that was obtained for the study,
the voluntary nature of participating, and the schedule of
compensation. RAs then answered any questions partici-
pants had and asked participants to sign an optional med-
ical chart release form (provided by the clinic) for chart
abstraction at the conclusion of the study. After being
assigned a four-digit ID number for the survey data, partic-
ipants completed an audio computer-assisted survey in-
strument (ACASI) on a laptop with the option to have
questions read aloud (in English or Spanish) through head-
phones. When participants finished with the baseline sur-
vey, they either returned to the waiting room to wait to be
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seen by the clinician(s) or went directly to an exam room
for their scheduled clinical visit. RAs communicated with
clinic staff to indicate which participants had taken the
baseline survey so that they could direct the patients (after
their clinical visits) back to the RAs for the exit survey.
Following clinical encounter
After the participants’ clinic visits, they were asked to
return to the private room with the RA to complete the
client exit survey, also completed using the ACASI pro-
gram on a laptop. Upon finishing this survey, RAs issued
$15 gift cards, local resource sheets, and appointment
reminder cards for the next follow survey to all partici-
pants. In intervention clinics, RAs also offered extra palm-
sized brochures to participants, explaining one was to
keep, and one was to give away to either a friend or family
member. Control clinic participants only received the one
page community resource sheet. When distributing bro-
chures and resource sheets to participants, RAs told par-
ticipants that taking these materials was voluntary, if they
felt safe taking the materials with them.
Procedures for post-visit assessments
After T1 is complete, RAs communicate with participants
via phone calls, texts, and emails to schedule the next two
surveys at the clinic, online, or by phone. If participants
gave RAs permission to leave voicemail messages, RAs
leave messages explaining that “It’s time to complete the
next step of the Women’s Health Study, please call
###-###-#### to make arrangements.” The RAs’ email
addresses used for correspondence to schedule surveys and
send online survey links lack features that identified the
true purpose of the study (for example: healthy9@pitt.edu).
Language used in the email titles and bodies is also general
and pertains to the “Women’s Health Study.”
Participants become eligible to complete their follow
up surveys at three months (T2) post baseline and again
at 12 months (T3) post baseline (Fig. 4). RAs schedule
times to meet participants back at the clinic to complete
the ACASI surveys. If participants 18 years and older are
unable to come to the clinic they are offered the option
of completing the survey online via Survey Monkey or
over the phone. If a participant cannot come to the
clinic and is under 18 year old, they are offered to the
option to complete the follow up surveys via phone.
If RAs are not able to contact a participant to schedule
the T2 schedule within the three to 6 month window
following baseline but regained contact thereafter, RAs
offer the option of completing an interview about their
experience with the study for $40 compensation. These
interviews assess the barriers participants experienced
such that they couldn’t complete T2 within the specified
time frame. The most common barriers were not having
time and not having access to a private computer to take
the survey online. At the conclusion of this non-
respondent interview (NRI), the interviewer worked with
the participant to schedule her T3 survey.
The sub-sample of intervention participants over age 18
who complete T3 either in-person or by phone are asked
whether they would be interested in learning about an
optional study component. Interested participants complete
a brief computerized screen to determine their eligibility for
a narrative interview about their experiences receiving the
intervention. The narrative interviews are intended for
women who have ever experienced IPV or RC, as the inter-
vention is likely to be most relevant for this subsample of
women. Eligible women respond affirmatively on this
screening survey to having ever experienced IPV or RC.
The RA explains the interview would include sharing her
relationship history as well as perspectives on receiving the
Fig. 4 Interview schedule. For patients not completing T2, a Non-respondent interview is collected to enhance retention at T3
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intervention in the clinic. These interviews are conducted
at the clinic at a time convenient for the woman, and she
receives $50 to thank her for her time. Survey data are not
connected to these anonymous narrative interviews.
At the conclusion of both T2 and T3 surveys, the
same protocol for distributing gift cards, resource sheets,
and safety cards is followed. If surveys are completed
online or by phone, gift cards are mailed to participants
with a generic return address that would not identify
their participation in this study.
At the conclusion of T3 data collection, available FP
medical records are reviewed for participants who had
signed authorizations allowing the study team to do so
(98 % of participants). RAs review visits spanning 12 months
pre-baseline to 18 months post-baseline to record number
and types of clinic visits, reasons for visits, pregnancy and
STI testing and diagnoses, documentation of assessment
for IPV and RC, and documentation of any disclosures of
IPV or RC.
Retention
Throughout the course of the study, research personnel
use multiple methods to keep participants engaged in the
study. One method is to call approximately 1–2 times per
month to verify contact information. In addition partici-
pants are contacted to set up follow up surveys approxi-
mately 4–6 weeks before their “due” date, and then are
reminded the day before and on the day of appointments.
If a participant misses their window for participation in the
T2 survey (beyond six months after baseline), they are con-
tacted for a non-respondent interview (described above)
where they are asked questions such as “We'd like to know
what some of the reasons were that you were not able to
do the survey?” and “What would have made it easier to
come back to do the survey?” This information informs
improvements to the protocol to add additional funds for
bus fare on women’s gift cards, as transportation (and not
having enough funds for gas) was a common reason stated
for not being to make it to appointments.
Power calculations and sample size
The planned recruitment of 3600 subjects from 25 clinics
in 17 clusters was designed to achieve 80 % power to detect
clinically significant effects of the intervention (under two-
sided testing at alpha = 0.05) for each of the specific hy-
potheses, after making appropriately cautious adjustments
for loss to follow-up, variance inflation arising from cluster
randomization, repeated follow-up measurements (of most
outcomes), the small number of denominator degrees of
freedom available when 17 clusters are used to assess the
effect of the intervention, and for the restriction of the Aim
2 analyses to subjects who reported recent IPV or RC
victimization at baseline. Reduction of RC and IPV by 50 %
(OR = 0.50) in both the full sample and subset experiencing
IPV/RC at baseline were specified as clinically significant ef-
fects. We also specified that reduction in recent unintended
pregnancy at the 12-month follow-up by 43 % (OR = 0.57)
in the full sample would represent a meaningful clinical
effect. Clinically significant effects were also specified for
other primary and secondary outcomes, corresponding to
intervention effect sizes of 0.20 standard deviations and
0.35 standard deviations for Aim 1 and Aim 2 analyses,
respectively.
Calculations were guided by results from our pilot
study, [26] allowing us to anticipate that the prevalence
of recent reproductive coercion in the control group
would be 10 % in the Aim 1 sample and 26 % in the
Aim 2 sample and we powered the study to detect
reduced prevalence of this outcome in the intervention
arm of 5.3 % and 14.9 % in the Aim 1 and Aim 2 ana-
lyses, respectively. Similarly, assuming the prevalence of
recent unintended pregnancy is 20 % in the control arm
at the 12-month follow-up (from pilot data), our study
was powered to detect a prevalence reduced to 12.5 % in
the intervention arm in the Aim 1 analysis.
Based on results from the pilot study, we anticipated
retaining at least 80 % of baseline subjects for the first
follow-up assessment. We further assumed that at least
75 % of the subjects from the first follow up would
also complete the second follow-up assessment, that
approximately 17 % of subjects would report recent
IPV victimization at baseline. To account for cluster
randomization design effects, we assumed that in our
planned regression analysis the residual within-person
and within-clinic correlations would be no higher than
25 % and 1 % respectively for key outcomes. The
above conditions indicate that our planned sample size
of 3600 patients and repeated measurements for most
outcomes would result in analyses that would provide
an effective sample size for Aim 1 analyses of at least
798 for assessing the unintended pregnancy outcome
(at the 12-month follow-up) and at least 1000 for the
other Aim 1 outcomes (where observations at both
follow-up occasions would be analyzed jointly – i.e.,
pooled T2 and T3 data). For the Aim 2, we anticipated
an effective sample size of at least 424 observations for the
other key outcomes in Aim 2 (where assessments from
both follow-up occasions would be analyzed jointly). If
attained, these effective sample sizes, based on prudently
cautious assumptions, ensure at least 80 % power to detect
clinically significant effects for the main outcomes in the
analyses for Aims 1 and 2.
Data safety and monitoring plan
The ARCHES intervention is focused on providing educa-
tion, relevant counseling and support for females ages 16
to 29 years seeking care in family planning clinics. The
pilot study enrolled over 1200 women, allowing for careful
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process evaluation to examine the impact of the interven-
tion on client and clinic provider safety. To our collabora-
tive team’s knowledge, no adverse events emerged in the
course of the pilot implementation. We ensured that the
intervention clinics received specific training on mandated
reporting requirements and how to conduct this reporting
in as safe and client-centered way as possible as an integral
part of the intervention. In addition to usual precautions
regarding protecting client privacy and confidentiality, we
also obtained a Certificate of Confidentiality to protect the
research data from subpoena. No requests for data oc-
curred during the pilot study. Despite the low risk associ-
ated with this behavioral intervention, we organized an
internal data safety and monitoring plan as well as an
external data safety and monitoring board. The In-
ternal Data Safety and Monitoring board is comprised
of the two Co-PIs (Miller and Silverman) and the
trainer from Futures Without Violence (Levenson).
The internal review board meets by conference call
once monthly and can confer on an as needed basis
should adverse or difficult events occur. The functions
of this internal DSM board are to:
a) Systematically review assessment materials to ensure
that assessment was conducted appropriately and
that participants disclosing abuse or violence receive
appropriate connection to violence-related services
and that mandated reports are made by clinicians
when appropriate.
b) Systematically review notes from research assistants
to ensure that participants experiencing distress
were connected directly with the on-site health care
provider, receiving educational materials, and being
referred appropriately; this included ensuring that all
research assistants documented asking each participant
about emotional distress after completion of the survey.
c) Conduct on-going preliminary data analyses to
evaluate the potential impact of the intervention on
specified outcomes of interest (knowledge,
self-efficacy, behaviors). In the unlikely event that
the intervention appeared to decrease the likelihood
of help seeking or increases the distress of partici-
pants, the study protocol would be reexamined and
modified appropriately.
d) Monitor staff performance with regard to protection
of privacy, confidentiality, maintenance of secure
databases, and study procedures designed to reduce
the risk of distress and potential breaches of
confidentiality.
e) Ensure that the PI (Miller), or a designated qualified
individual, is available by pager in case research staff
needed to confer regarding participant symptoms.
f ) Review and report any adverse events associated
with the study.
The current project involves monitoring activity across
25 clinics, a much larger undertaking than the pilot study,
with follow up of clients up to 15 months from baseline.
Given the complexity of this project, in addition to the
internal monitoring noted above, we instituted an External
Data Safety and Monitoring Board. This external monitor-
ing group consisted of the Quality Assurance Director from
Adagio Health, the Vice President of Operations from
Planned Parenthood Western Pennsylvania, and Director
of Health from Futures Without Violence. All three individ-
uals are familiar with the details of the research protocol,
but not intimately involved in the day to day implementa-
tion. They also have the authority to suspend the project
should any challenges or adverse events arise, and to direct
changes in clinic policies and research protocol should site-
specific problems emerge. For example, should a client
experience emotional distress and the research assistant
notified designated clinic staff but the staff is not respon-
sive, this would be reported immediately to the Internal
DSMB as well as the External DSMB, and changes would
be implemented before proceeding with any further data
collection.
Patient accrual and study flow
25 clinics were combined into 17 clinic clusters for
randomization, 8 intervention and 9 control clusters
(Fig. 5). From intervention sites a total of 3958 women
were approached, 2140 who were excluded either
because they didn’t meet inclusion criteria or because
they declined to participate, and from control clinics a
total of 4259 were approached with 2390 being ex-
cluded leaving 3687 who were enrolled into the study
and completed the baseline survey (Table 2).
Planned analytic approach
Overview
Following a sequence of preliminary analyses to characterize
the sample participants and outcome measures, statistical
methods for cluster-randomized experimental studies will
be used to assess study hypotheses. The anticipated study
data is multilevel, with baseline and follow-up data col-
lected from patients, the units of analysis, who are nested
within clinics, the units of randomization. The primary
assessment of intervention effects will be based on intent-
to-treat estimates. As-treated effect parameters will be es-
timated in secondary analyses and reported as exploratory.
Following preliminary phases of descriptive, bivariate and
multivariate analyses to characterize the sample and to re-
fine and characterize scale-based outcome measures, esti-
mates and hypothesis testing will be conducted in a
multilevel generalized linear mixed (regression) modeling
framework that will specify within-clinic and within-
patient cluster effects. Regression models will include a
parsimonious set of covariates to adjust for the restricted
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stratified randomization of clinics, to reduce the potential
for confounding arising from between-arm imbalances in
patient and clinic characteristics, and to increase the pre-
cision of intervention effects, with the specification of link
and variance functions tailored to the type of outcome
variable (e.g., logistic links for binary outcomes).
Two types of biases will be specifically explored using
statistical testing. Participation bias will be assessed by
comparison of age, race/ethnicity, and other demo-
graphics of clients participating in the study with that
of the demographics of the overall family planning
clinic clients (at participating sites) during the period of
data collection, with significant differences noted as po-
tential threats to generalizability. Descriptive statistics
and bivariate and multivariate analyses will characterize
patient demographics and compare groups with respect
to key baseline measures. Variables differing across
treatment groups at the p < .20 level will be included as
covariates in subsequent adjusted outcome analyses. A
similar set of analyses will be conducted to compare
those who complete all three visits to those who do not
to assess attrition bias. If between-arm differences in
attrition are found, this potential validity threat will be
noted.
Outcome analyses
We will use generalized linear mixed effects models for
evaluating the effect of the intervention on follow-up
outcomes. Separate models will be created for each out-
come, and predictors will include a parsimonious set of
important covariates, including potential confounders
identified in preliminary analyses, the baseline measure
Fig. 5 CONSORT flow diagram
Tancredi et al. BMC Women's Health  (2015) 15:57 Page 12 of 16
of the outcome (when available), and a clinic-level binary
indicator for whether the patient was in a treatment (vs.
control) clinic. Random effects will be specified to ac-
count for the nesting of patients within clinic and, where
appropriate, for repeated follow-up measurements. Rec-
ognition of sexual coercion, reproductive coercion, and
physical and sexual partner violence baseline measures
will be available for all time points and thus baseline
measures will be included as covariates in the respective
models to improve the precision of our estimated
intervention effects. Within-clinic and within-patient
cluster effects will be specified as random effects in the
models.
For Aim 2 hypotheses, the analysis will be restricted to
the patients who report at baseline having recently expe-
rienced physical or sexual partner violence or reproduct-
ive coercion.
Following the definitive assessments of key study hypoth-
eses, a series of exploratory analyses will be conducted. In
particular, the potential for differential impact of the inter-
vention based on patient characteristics will be evaluated,
with a view toward identifying factors (e.g., race/ethnicity,
age, immigrant status, involvement in commercial sex) that
may facilitate or impede the efficacy of the intervention,
and to identify patient subgroups most receptive to the
intervention or that may require further assistance.
For each outcome, we will use all eligible records at both
follow-up visits to model timepoint-specific intervention
effects, with the first model specifying (TIMEPOINT x
INTERVENTION) interaction terms to permit testing for
homogeneity, using Wald-tests with a statistical signifi-
cance threshold of 0.05. For outcomes without statistically
significantly heterogeneous intervention effects, the pri-
mary assessment of the intervention will involve the over-
all main effect of the intervention (versus the control),
pooled across both follow-up occasions. Otherwise, time-
point specific contrasts will be used for the primary
assessment of the intervention on the outcome. Each out-
come will be assessed with a two-tailed alpha = 0.05. No
adjustments for multiple testing will be made, as we feel
that each of these hypotheses is of independent scientific
interest. Graphical and analytical methods will be used to
examine model fit and to evaluate assumptions used to
justify inferences.
Missing data
The eligible population for these analyses is restricted
to measurements from women who report (i.e., at the
given timepoint) having heterosexual sexual intercourse
(vaginal, oral, or anal). At each timepoint, this eligibility
criterion was reassessed and further survey data neces-
sary for defining outcome variables at that timepoint
were collected only when this criterion was met. For
women with follow-up data for whom the baseline sur-
vey did not collect responses needed to compute base-
line covariates to be used in the mixed-effects models,
baseline covariate values will be imputed.
In addition, for intermittently missing values (e.g.,
when the respondent selected “don’t know” or “refuse to
answer”) for items in eligible follow-up visits, values will
be imputed using multiple imputation (Markov Chain
Monte Carlo algorithm) procedures in SAS PROC MI
and PROC MIANALYSE for the imputation and ana-
lyses steps, respectively.
Table 2 Demographics of total collected sample (n = 3687)
Characteristic Total %a (n)
Age
16–20 37.7 (1387)
21–24 35.6 (1310)
25–29 26.8 (986)
Race
White 80.1 (2951)
Black/African American 13.4 (492)
Hispanic/Latina 1.6 (59)
Multi-racial 3.0 (110)
Other 1.6 (59)
Education
Less than 12th grade 19.2 (707)
Finished high school 27.0 (995)
Some college 32.9 (1211)
Finished college or grad school 20.3 (748)
US Born
Yes 98.2 (3615)
No 1.8 (65)
Relationship Status
Single 32.1 (1181)
Dating more than one person 1.5 (56)
Dating one person/in a serious relationship 58.3 (2148)
Married 7.0 (259)
Married with more sex partners than husband 0.2 (7)
Ever had sexual intercourse
Yes 97.9 (3604)
No 1.9 (69)
Sex of Sexual Partnersb
Men only 88.6 (3184)
Mostly men 7.8 (279)
Equally men and women 1.6 (58)
Mostly women 0.3 (12)
Women only 1.7 (62)
a%s may not equal 100 % due to small amounts of missing data
bOf those who report ever having had sexual intercourse
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Discussion
This community-partnered study tests a brief intervention
to reduce risk for intimate partner violence (IPV) and re-
productive coercion, with the goal of reducing unintended
pregnancy among young, medically-underserved women
attending family planning (FP) clinics. IPV is experienced
by a disproportionately large number of women seeking
care in FP clinics, and experiences of IPV have consistently
been observed to relate to higher risk for unintended preg-
nancy. A team of researchers, clinicians, advocates, and FP
clients, collaborated to develop the ARCHES intervention
that integrates universal education and assessment for
reproductive coercion (a recently identified phenomenon
strongly associated with IPV and unintended preg-
nancy) and related harm reduction strategies into
standard FP care. Delivered via the existing clinic struc-
ture of family planning counseling and clinical services,
this intervention is not only innovative, but sustainable
and replicable. Thus, if found effective, this intervention
may be scaled-up at relatively low cost to address the
intertwined major public health concerns of unintended
pregnancy and IPV.
Our pilot study confirmed the acceptability and feasibility
of this intervention, and demonstrated a significant reduc-
tion in pregnancy coercion at follow-up among women
reporting recent IPV. This larger-scale cluster-randomized
controlled trial engaged a greater number of clinics (N = 17
clusters) and participants (N = 3687) for a longer trial dur-
ation (12 months) to achieve sufficient statistical power and
length of time post-baseline to assess for reductions in key
outcomes - IPV victimization, reproductive coercion, and
unintended pregnancy.
In conducting the trial, we encountered several chal-
lenges and limitations:
 While we attempted to enroll a large number of
clinics, due to the overlap of staff and clinicians
across sites, 25 clinics resulted in only 17 clusters.
 After randomization, one of the intervention clinics
closed before we could enroll participants (one of
two clinics in a rural cluster), resulting in 24 clinics.
After T1 data collection was completed, another
intervention clinic (urban) closed. Because of the
research team’s system for obtaining multiple ways
to contact participants, many of the participants
from that clinic could be found and could complete
the survey at another clinic location in downtown
Pittsburgh (or via email or phone).
 While the survey was available in Spanish, almost all
the participants were English speaking,
predominantly White, with very small numbers of
non-African American minorities in this sample,
limiting the generalizability of study findings to
more diverse settings across the U.S.
In summary, the results of this RCT will address the
question of whether brief universal IPV/RC education and
counseling intervention for IPV and RC in family planning
clinic settings can help to reduce risk for IPV and RC and,
in turn, decrease unintended pregnancy. The trial will also
examine how this intervention may affect women who have
recently experienced IPV or RC, with attention to their use
of IPV resources and disclosure to health care providers, in
addition to the overall primary and secondary outcomes.
Additional process evaluation including interviews with
clients and providers will provide information on barriers,
challenges, and facilitators of intervention implementation.
This study will contribute to the growing evidence base on
the utility of brief educational and counseling interventions
in clinical settings to address IPV an RC; additionally, les-
sons learned from this clinical intervention implementation
may guide the design and implementation of similar inter-
ventions to increase overall health and well-being.
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